Cargando…

Improving resource utilisation in SLE drug development through innovative trial design

SLE is a complex autoimmune disease with considerable unmet need. Numerous clinical trials designed to investigate novel therapies are actively enrolling patients straining limited resources and creating inefficiencies that increase enrolment challenges. This has motivated investigators developing n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garces, Sandra, Karis, Elaine, Merrill, Joan T, Askanase, Anca D, Kalunian, Kenneth, Mo, May, Milmont, Cassandra E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373732/ https://www.ncbi.nlm.nih.gov/pubmed/37491104 http://dx.doi.org/10.1136/lupus-2022-000890

Ejemplares similares

SARS-CoV-2 vaccines in patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

The Use of COVID-19 Vaccines in Patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

Hydroxychloroquine Use Is Not Associated With QTc Length in a Large Cohort of SLE and RA Patients
por: Park, Elizabeth, et al.
Publicado: (2021)

Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020)

Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients
por: Park, Elizabeth, et al.
Publicado: (2021)

Prevalence of coronary artery calcification in young patients with SLE of predominantly Hispanic and African–American descent
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2019)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
por: Askanase, Anca D, et al.
Publicado: (2020)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey
por: Birt, Julie A., et al.
Publicado: (2021)

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
por: Mendel, Arielle, et al.
Publicado: (2019)

Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity
por: Askanase, Anca D., et al.
Publicado: (2019)

Expenditure and resource utilisation for cervical screening in Australia
por: Lew, Jie-Bin, et al.
Publicado: (2012)

Optimal utilisation of sulphonylureas in resource-constrained settings
por: Naidoo, Poobalan, et al.
Publicado: (2014)

The resource utilisation of medically unexplained physical symptoms
por: Lee, Kimberley, et al.
Publicado: (2016)

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006
por: Strand, Vibeke, et al.
Publicado: (2014)

SLE and APS
por: Avcin, Tadej
Publicado: (2014)

Epigenetics in SLE
por: Hedrich, Christian Michael
Publicado: (2017)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Out-of-hospital cardiac arrest and resource utilisation in the ICU
por: Manning, A, et al.
Publicado: (2010)

Resource utilisation among patients transferred for intracerebral haemorrhage
por: Zachrison, Kori Sauser, et al.
Publicado: (2019)

Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD
por: Ronco, Raffaella, et al.
Publicado: (2023)

Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus
por: Aberle, Teresa, et al.
Publicado: (2017)

Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments
por: Askanase, Anca, et al.
Publicado: (2015)

Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

Hydroxychloroquine in SLE: old drug, new perspectives
por: Dörner, Thomas
Publicado: (2010)

SLE - Rituximab in lupus
por: Eisenberg, Robert
Publicado: (2003)

1. SLE and Pregnancy
por: Khan, Afsha, et al.
Publicado: (2017)

SLE: reconciling heterogeneity
por: Lockshin, Michael D, et al.
Publicado: (2019)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

COVID-19 after rituximab therapy in cSLE patients
por: Nelson, Meghan Corrigan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hjvh0h741favvomqta202au0fb